Form 4: Beyond Air CEO Steven Lisi Acquires Shares and Warrants in Private Placement and Loan Agreement

Beyond Air's CEO, Steven Lisi, acquired shares, pre-funded warrants, and common warrants through a private placement and a loan agreement with the company.

Summary

• On September 26, 2024, Beyond Air's CEO, Steven Lisi, acquired 1,476,626 shares of common stock at $0.5043 per share.
• Lisi also acquired pre-funded warrants to purchase 506,321 shares at an exercise price of $0.0001 per share.
• Additionally, he obtained common warrants to acquire 1,982,947 shares at an exercise price of $0.3793 per share.
• These acquisitions were made through a Securities Purchase Agreement dated September 26, 2024.
• On September 27, 2024, Lisi acquired warrants to purchase up to 3,295,544 shares of Common Stock in connection with a $2,500,000 loan to the Issuer.
• The warrants will be exercisable on or after the date on which the Company obtains stockholder approval and will expire five years following such date they are exercisable.

Sentiment

Score: 7

Explanation: The CEO's investment is generally a positive sign, indicating confidence in the company's future. However, the need for a loan and private placement also suggests the company may be facing financial challenges.

Positives

• The CEO's investment in the company may signal confidence in Beyond Air's future prospects.
• The capital injection from the loan agreement could provide the company with necessary funds for operations or expansion.

Risks

• The exercise of the warrants is contingent upon stockholder approval, which introduces uncertainty.
• The loan agreement could increase the company's debt burden.

Future Outlook

The pre-funded and common warrants will be exercisable on or after the date on which the Company obtains stockholder approval. The common warrants will have a term that expires five years following the Initial Exercise Date.

Industry Context

This type of transaction, where a CEO invests in their own company through private placements and loan agreements, is not uncommon, especially for smaller companies seeking capital. It can be seen as a positive signal if the market believes in the CEO's vision and commitment.

Comparison to Industry Standards

• Comparing this transaction to similar private placements in the biotech industry, the pricing and terms appear to be within a reasonable range, considering Beyond Air's market capitalization and growth stage.
• Similar companies, such as Aytu BioScience (now Innovus Pharma) and Diffusion Pharmaceuticals, have utilized private placements and warrant offerings to raise capital.
• The warrant exercise prices are typical for such offerings, often set at a premium or discount to the current market price.

Related Party Transactions

• The acquisition of shares and warrants by the CEO, Steven Lisi, is a related party transaction that requires disclosure.

Stakeholder Impact

• Shareholders may view the CEO's investment positively, potentially increasing investor confidence.
• Employees may benefit from the company's improved financial position due to the capital injection.
• Creditors may be impacted by the new loan agreement.

Next Steps

• The company needs to obtain stockholder approval for the exercise of the pre-funded and common warrants.
• The company will likely use the raised capital for operational expenses or strategic initiatives.

Key Dates